Qld biotech Vaxxas to develop needle-free vaccine in Brisbane – World News

Qld biotech Vaxxas to develop needle-free vaccine in Brisbane

A new vaccine option with ‘world-leading’ technology will be available in Australia for those with a fear of needles.

Queensland biotech company Vaxxas will develop and manufacture needle-free vaccines as health officials stress the importance of booster COVID-19 jabs.

The “world-leading” technology would be warmly welcomed for people with needle phobia, but Vaxas chief operating officer Angus Forster said its simple application was ideal for underdeveloped countries and remote communities.

The dose is administered via a “high-density micro-array patch,” which is applied to the skin for 10 seconds at a depth of only a quarter millimeter.

“Our clinical research shows that it elicits a more efficient and effective immune response than conventional syringes due to the abundance of immune cells just below the surface of the skin,” he said.

“There is also an opportunity to greatly simplify the transportation of vaccines to rural and remote communities because vaccine patches can be stored at temperatures up to 40ºC.”

The patch will be used initially for influenza vaccines, which are intended to be rolled out for a variety of jabs, including COVID-19 vaccines.

Deputy Premier Steven Miles said construction had begun at the company’s manufacturing facility in Hamilton, north of Brisbane, which is expected to be completed by 2023.

Once the manufacturing plant is operational, Vaxxas will produce 300 million vaccine doses each year.

“An existing warehouse in Northshore, Brisbane, will be refurbished and transformed into a state-of-the-art biomedical manufacturing facility, creating over 80 jobs during construction,” said Mr Miles.

“Over the next 10 years, this rate of production is expected to contribute hundreds of millions of dollars to the Queensland economy.

VAXAS will employ 110 highly-skilled biomedical specialists when it operates in early 2023. This could increase to more than 139 new jobs in five years, which will go a long way in securing Queensland as a globally competitive Asia-Pacific biomedical hub. ,

Reliance on vaccines will continue as pandemic develops, reveals pharmaceutical giant Pfizer may have two shots of its jab not being enough To defend against the Omicron version.

Pfizer on Wednesday announced the results of a preliminary laboratory study that three doses of the vaccine may be needed to produce enough antibodies to “neutralize” the Omicron COVID-19 variant.

The results showed that sera, a fluid obtained from isolating blood, from individuals receiving two doses of the current COVID-19 vaccine displayed, on average, “25 in neutralization titers against the Omicron variant compared to wild”. fold reduction”. Type”.

Read related topics:Brisbane

,

Source link

Leave a Comment

Your email address will not be published. Required fields are marked *